ICLR
ICON Public Limited Company
NASDAQ · Healthcare · Medical - Diagnostics & Research · IE
$164.49
+0.56%Aug 6, 2026, 10:30 UTC
ICON priced USD 2.15 billion in notes on August 6, 2026.
Source:Aug 1, 2026, 08:05 UTC
Avidity Partners Management LP reduced its stake in Icon Plc by 51.7% during the second quarter of 2026, selling 17,100 shares and retaining 16,000 shares, as disclosed in its Form 13F filing with the SEC.
Source:Jul 30, 2026, 01:36 UTC
Icon PLC reported Q2 2026 earnings of $2.56 per share, missing the Zacks Consensus Estimate of $2.57 per share, compared to $3.26 per share a year ago.
Source:Jul 28, 2026, 11:01 UTC
Icon Group has entered a partnership to apply CLAUDE in clinical trials.
Jun 23, 2026, 20:15 UTC
ICON reported its first quarter 2026 financial results, including revenue of $2,034.0 million and GAAP net income of $104.8 million.
Source:Jun 22, 2026, 11:00 UTC
ICON plc selected Microsoft as a preferred technology partner to power AI-enabled clinical development.
Source:Jun 5, 2026, 19:10 UTC
ICON plc disclosed an accounting restatement and flagged control weaknesses.
Source:May 30, 2026, 13:57 UTC
ICON Public Limited Company identified improper revenue recognition adjustments and material weaknesses in internal controls, resulting in a cumulative revenue overstatement of $158 million across 2023 and 2024.
Source: